Join to View Full Profile
5841 S Maryland AveChicago, IL 60637
Phone+1 888-824-0200
Fax+1 773-702-0963
Are you Dr. Thirman?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Michael Thirman, MD is an oncologist in Chicago, Illinois. He is currently licensed to practice medicine in Illinois and Minnesota. He is an Associate Professor of Medicine at University of Chicago Medicine.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 1990 - 1994
University of MinnesotaResidency, Internal Medicine, 1986 - 1989
University of Michigan Medical SchoolClass of 1986
Certifications & Licensure
IL State Medical License 1990 - 2026
MN State Medical License 1989 - 1990
American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 16 citationsMenin Inhibition With Revumenib for-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman, John DiPersio, Martha Arellano
Journal of Clinical Oncology. 2025-01-01 - 20 citationsGenetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.Hartmut Döhner, Keith W Pratz, Courtney D DiNardo, Andrew H Wei, Brian A Jonas
Blood. 2024-11-21 - Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.Rafael Madero-Marroquin, Emily Dworkin, Howard Weiner, Caner Saygin, Mariam T Nawas
Leukemia & Lymphoma. 2024-06-01
Authored Content
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Join now to see all
Press Mentions
203 UChicago Medicine Doctors Named to 2022 Top Docs ListJanuary 21st, 2022
Long-Sought Genetic Model of Common Infant Leukemia DescribedNovember 10th, 2016
